There is a peculiar moment in medicine when a discovery stops belonging only to the people who discovered it. The data must travel. It leaves the statistician’s table and lands in a manuscript, a congress poster, a physician’s slide deck, a sales aid, a website, perhaps a patient’s anxious late-night search. At every stop, the audience changes. The facts cannot.
Synchrony Group has made a business out of that journey. From a brick-walled office in downtown West Chester, Pennsylvania, the independent agency group works between the clinical result and the human decision. Its people analyze evidence, find the governing idea, and then express that idea in forms ranging from scientific publications to brand campaigns.
This is not simply “making complicated things simple.” Simplification can remove the very caveat that makes a medical claim true. The harder task is compression without distortion - preserving enough scientific structure that the message remains accurate while making it clear enough to be remembered and used.
Two agencies, one scientific spine
Rod Hughes, a PhD who remains founder and chief executive, started Synchrony in 2007. The company was built around strategic planning and the execution of medical-communications programs. It now presents itself as a group with two complementary specialists. Synchrony Medical Communications handles the scientific side: publication planning, manuscripts, medical education, medical-affairs support, scientific platforms, expert engagement, and training. Synchrony Healthcare Communications works on the commercial side: disease-state education, brand positioning, promotional campaigns, digital experiences, video, and design.
The division matters because a life-sciences company rarely has only one audience. The same body of evidence may need to serve a medical-science liaison, a journal reviewer, a specialist physician, a sales representative, and a patient. Those are not five versions of the same brochure. They are five different situations, each with its own purpose, vocabulary, and rules.
The business model is the classic specialist agency model: life-sciences companies pay for strategic counsel, scientific content, creative development, production, and ongoing program support. The buyers sit in medical affairs, publications, brand, commercial, training, or related functions. Unlike a software company, Synchrony does not sell a fixed product at a fixed price. Scope, therapeutic complexity, format, review burden, and duration shape the engagement.
“We become experts in the science through rigorous analysis of the product and therapeutic landscape.”Synchrony Group
The four verbs
Synchrony’s most useful piece of self-description is a string of verbs: analyze, strategize, visualize, synchronize. Many agencies turn their process into a diagram. This one works because it names four genuinely different kinds of labor.
The operating system
Analysis comes first because the obvious message is not always the useful one. Strategy decides what should change in the audience’s understanding or behavior. Visualization makes the idea tangible. Synchronization is the unglamorous final requirement: medical, legal, regulatory, commercial, creative, and client teams all have to move in the same direction.
That process suits specialty products and rare diseases, areas the company explicitly emphasizes. In a common disease, an audience may already understand the condition. In a rare one, the communicator may need to explain the disease, its mechanism, its diagnostic delays, the patient burden, and the relevance of a new therapy before a product claim can mean anything at all.
The campaign that kept growing new limbs
Synchrony’s work with Harmony Biosciences offers the clearest public view of what this looks like. Around WAKIX, a treatment associated with narcolepsy, the work expanded across an interactive healthcare-professional website, a core visual aid, patient-story videos, and an interactive 3D brain model explaining histamine’s role in stabilizing wakefulness.
The formats accumulated recognition: Gold for the WAKIX HCP website in the 2021 PM360 Pharma Choice Awards; a 2021 Pharmaceutical Executive APEX Award; PM360 Trailblazer recognition in 2022 for the visual aid and patient-story video series; and Bronze in the 2023 Pharma Choice Awards for the 3D model. In 2024, five Harmony initiatives involving Synchrony and other agency partners reached the PM360 Trailblazer finalist list.
Awards are imperfect evidence - agencies enter some work and not other work, and juries see only the finished artifact. But the sequence tells us something. This was not a clever execution dropped onto an unrelated strategy. One scientific subject supported multiple experiences over several years. The reusable asset was the narrative underneath.
It also shows where Synchrony sits in the market. Giant healthcare networks can offer global media buying, public relations, consulting, advertising, and technology at vast scale. Small medical-writing shops can offer focused scientific production. Synchrony occupies the middle: an independent group large enough to join scientific and creative disciplines, specialized enough to make therapeutic complexity part of the pitch.
What another team can copy
You do not need a medical-communications agency to borrow the useful part of its method. You need a problem where accuracy matters, several audiences interpret the same evidence differently, and the final message must change a decision.
Build the spine before the limbs
- Start with the evidence, including the awkward caveats.
- Define the decision each audience needs to make.
- Write one durable narrative before choosing formats.
- Adapt the expression, not the underlying truth.
- Bring reviewers into the logic early, not merely the approval late.
This approach is less useful when the assignment is a commodity message, a low-stakes announcement, or a rapid social response where exhaustive cross-functional alignment costs more than it returns. It also fails when “alignment” becomes a polite word for committee writing. A scientific spine should keep the work coherent. It should not make every sentence sound as if twelve people negotiated it.
The company itself has entered a new stage. In November 2025, Synchrony named Sonja Foster-Storch president, with responsibility for operations and organizational advancement, while Hughes continued as founder and CEO. The announcement said the workforce had more than doubled in recent years. For an agency built on synchronization, growth creates a pointed test: can the method survive more people, more categories, and more handoffs?
The answer will not be found in the loudest campaign. It will be found in whether a clinician sees the point sooner, whether a medical team can use the same narrative across channels, and whether a patient meets information that respects both the science and the person reading it. The journey from evidence to action is long. Synchrony’s bet is that it can be made coherent.